Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iparomlimab + tuvonralimab + lenvatinib
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Iparomlimab + tuvonralimab + lenvatinib is a combination therapy being investigated for the neoadjuvant treatment of hepatocellular carcinoma (HCC). This regimen combines two bispecific antibodies developed by Akeso Biopharma with a multi-kinase inhibitor. **Iparomlimab** (cadonilimab) is a first-in-class bispecific antibody targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), designed to enhance anti-tumor immune responses while potentially reducing the toxicity associated with combining separate PD-1 and CTLA-4 inhibitors. **Tuvonralimab** (ivonescimab) is a bispecific antibody targeting PD-1 and vascular endothelial growth factor (VEGF), intended to simultaneously block immune escape and inhibit tumor angiogenesis. **Lenvatinib** is an oral receptor tyrosine kinase inhibitor that targets VEGF receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), PDGFRα, KIT, and RET. The combination aims to leverage synergistic effects by targeting multiple pathways involved in tumor growth, immune evasion, and vascularization.
- Brand names
- Kaitanni
- Other names
- cadonilimab + ivonescimab + lenvatinibIparomlimab and Tuvonralimab Injection combined with lenvatinib
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)FGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on iparomlimab + tuvonralimab + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iparomlimab + tuvonralimab + lenvatinib.